|
|
 |
|
Viewing report
|
|
|
|
Commercial Insight: Antihormonal Cancer Therapies - Leading brands strive to minimize generic sales erosion
Datamonitor, July 2010, Pages: 111
Introduction
Antihormonal cancer therapies are a class of drugs used predominantly in the treatment of breast cancer and prostate cancer. The high incidence of these tumor types translates into a significant commercial potential for drug developers. Collectively, the antihormonal therapy cancer brands generated sales of about $7.0 billion in the seven major pharmaceutical markets in 2009.
Scope
-In-depth analysis of the current and future antihormonal therapies market across the US, 5EU and Japan, plus a rest of world snapshot
-Antihormonal therapy sales forecasts for brands and generics from 2009 to 2019
-Assessment of the leading cancer brands and drug classes to identify key success factors within this sector
-Evaluation of the strategies of leading players in the antihormonals market
Highlights
The antihormonals market was worth $7.0 billion in 2009 across the seven major pharmaceutical markets. Datamonitor forecasts the antihormonals market will shrink marginally in the forecast period 20092019, at a CAGR of negative 0.7%.
In 2019 the top three brands in terms of forecast sales will be Arimidex, Lupron (leuprolide; Takeda/Abbott) and Casodex (bicalutamide; AstraZeneca). Despite losing around 54% of its current sales value to generic competitors, Arimidex will retain its market leading position.
In a mature market, the importance of product lifecycle management is high. AstraZeneca was the key player in the market in 2009, with an antihormonals portfolio valued at over $3.2 billion. With successful lifecycle management and a considerable investment in marketing activities, AstraZeneca has built a strong brand presence for its products.
Reasons to Purchase
-Quantify the performance of each of the marketed antihormonal therapy cancer brands in the seven major markets over the period 2009 to 2019
-Acquire a detailed account of antihormonal therapy cancer brand dynamics and the events that drive and limit their market growth
-Benchmark antihormonal therapy cancer brands against their generics and rest of class and align their 7MM performance with a rest of world snapshot
Customers who bought this item also bought
Commercial Insight: Cytotoxic Therapies - Drug launches in rare indications to offset the decline in cytotoxic sales
Commercial Insight: Cancer Targeted Therapies and Immunotherapies -Top monoclonal antibody brands will resist competitive pressures through to 2019
Pipeline and Commercial Insight: Allergic Rhinitis - Immunotherapy Growth Surpassed by Generic Erosion
Oncology Market Forecast to 2015: Brand Spending and Development Opportunities
Commercial Insight: Top 20 Cancer Therapy Brands
Forecast Insight: HIV - Increasing dominance of fixed dose combinations raises bar for single agents
Commercial Insight: Osteoporosis - Market players maximize revenue growth before the next challenging phase
Lung Cancer Therapeutics Market Outlook and Pipeline Analysis
Forecast Insight: Hepatitis B - Baraclude and Viread set to thrive in the face of limited competition
Prostate Cancer Drug Discoveries: What the Future Holds
|
|
|
|
